Enabling the next generation in search of blood cancer cures

HORIZON.1.2HORIZON-TMA-MSCA-Cofund-DID: 101126688
EC Contribution
โ‚ฌ18,816
Consortium Size
47 orgs
โ–ถSummary

The CarrerasPathfinder program is new a world-wide unique doctoral program that covers the entire spectrum of research and innovation in blood cancers from understanding disease biology to the implementation of novel processes in the clinical practice. The program will fund 14 excellent Doctoral Candidates (DCs) for a period of 48 months. DCs will perform collaborative PhD projects involving associated partners from different sectors, countries, and disciplines through secondments. DCs will improve their research capacity and transferable skills through high-quality supervision arrangements and a tailored training program.The program has been designed and will be hosted by the Josep Carreras Leukaemia Research Institute (IJC) which is the first European non-profit institute exclusively devoted to blood cancers. By answering the European needs for human resources, it is fully aligned with the 13 recommendations of the EU Cancer Boardโ€™s Draft Mission and the Europeโ€™s Beating Cancer Plan (2021). The CarrerasPathfinder program has a strong triple-I dimension of internationality, inter-sectorality and interdisciplinarity in training, networking, co-supervision and research. Its specific objectives are:โ€ขTo develop an excellent doctoral program in blood cancer research conceived as a pilot for a permanent international doctoral programโ€ขTo equip DCs with a unique skill set boosting effectiveness and innovation capacity. โ€ขTo promote DCsโ€™ career development and increase their employability in different sectors.โ€ขTo establish the IJC as a European reference for research and training in blood cancers.โ€ขTo provide Europe with a new generation of researchers able to address unmet needs and societal challenges of blood cancers.โ€ขTo contribute to structuring the European research area by collaborating and synergizing with other European key opinion leaders.

Consortium (47)

๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO INSTITUT DE RECERCA CONTRA LA LEUCEMIA JOSEP CARRERASES
coordinator
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
partner
๐Ÿ‡ช๐Ÿ‡ธ ANAXOMICS BIOTECH SLES
partner
๐Ÿ‡ช๐Ÿ‡ธ APPLIED NANOPARTICLES SLES
partner
๐Ÿ‡ช๐Ÿ‡ธ APPLIED RESEARCH USING OMIC SCIENCES SLES
partner
๐Ÿ‡ช๐Ÿ‡ธ Asociaciรณn Espaรฑola Contra el CรกncerES
partner
๐Ÿ‡ช๐Ÿ‡ธ ASOCIACION INNOLIFE SPAINES
partner
๐Ÿ‡ช๐Ÿ‡ธ BARCELONA SUPERCOMPUTING CENTER CENTRO NACIONAL DE SUPERCOMPUTACIONES
partner
๐Ÿ‡ช๐Ÿ‡ธ BIOCAT LA FUNDACIO BIOREGIO DE CATALUNYAES
partner
๐Ÿ‡ธ๐Ÿ‡ฐ BIOMEDICINSKE CENTRUM SLOVENSKEJ AKADEMIE VIED, VEREJNA VYSKUMNA INSTITUCIASK
partner
๐Ÿ‡ฉ๐Ÿ‡ช CHARITE - UNIVERSITAETSMEDIZIN BERLINDE
partner
๐Ÿ‡ช๐Ÿ‡ธ CONSORCIO PARA LA CONSTRUCCION EQUIPAMIENTO Y EXPLOTACION DEL LABORATORIO DE LUZ SINCROTRONES
partner
๐Ÿ‡ฉ๐Ÿ‡ช DEUTSCHES KREBSFORSCHUNGSZENTRUM HEIDELBERGDE
partner
๐Ÿ‡จ๐Ÿ‡ญ ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNECH
partner
๐Ÿ‡ณ๐Ÿ‡ฑ EUROPEAN HEMATOLOGY ASSOCIATIONNL
partner
๐Ÿ‡จ๐Ÿ‡ญ FONDAZIONE PER L'ISTITUTO ONCOLOGICO DI RICERCA (IOR)CH
partner
๐Ÿ‡ต๐Ÿ‡น FUNDACAO GIMM - GULBENKIAN INSTITUTE FOR MOLECULAR MEDICINEPT
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO INSTITUCIO DELS CENTRES DE RECERCA DE CATALUNYAES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACIO INSTITUT DE RECERCA BIOMEDICA (IRB BARCELONA)ES
partner
๐Ÿ‡ช๐Ÿ‡ธ Fundaciรณ Internacional Josep CarrerasES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION CIENTIFICA DE LA ASOCIACIร“N ESPANOLA CONTRA EL CANCERES
partner
๐Ÿ‡ช๐Ÿ‡ธ FUNDACION PARA EL CONOCIMIENTO MADRIMASDES
partner
๐Ÿ‡ช๐Ÿ‡ธ Gavin LucasES
partner
๐Ÿ‡ฎ๐Ÿ‡น HUMANITAS MIRASOLE SPAIT
partner
๐Ÿ‡ท๐Ÿ‡ด INSTITUTUL NATIONAL DE CERCETARE - DEZVOLTARE IN DOMENIUL PATOLOGIEI SI STIINTELOR BIOMEDICALE VICTOR BABES RARO
partner
๐Ÿ‡บ๐Ÿ‡ธ International Society for Experimental HematologyUS
partner
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
partner
๐Ÿ‡ช๐Ÿ‡ธ MESOESTETIC PHARMA GROUP S.L.ES
partner
๐Ÿ‡ฉ๐Ÿ‡ช MLL MUNCHNER LEUKAMIELABOR GMBHDE
partner
๐Ÿ‡บ๐Ÿ‡ธ NEW YORK UNIVERSITYUS
partner
๐Ÿ‡ฌ๐Ÿ‡ง NOVOGENE UK COMPANY LIMITEDGB
partner
๐Ÿ‡ช๐Ÿ‡ธ ONECHAIN IMMUNOTHERAPEUTICS S.L.ES
partner
๐Ÿ‡ธ๐Ÿ‡ฎ ONKOLOSKI INSTITUT LJUBLJANASI
partner
๐Ÿ‡ช๐Ÿ‡ธ QUIMATRYX SLES
partner
๐Ÿ‡ช๐Ÿ‡ธ SCIENSEED SLES
partner
๐Ÿ‡ญ๐Ÿ‡บ SEMMELWEIS EGYETEMHU
partner
๐Ÿ‡ง๐Ÿ‡ฌ Specialized Hospital for Active Treatment of Hematological DiseasesBG
partner
๐Ÿ‡บ๐Ÿ‡ธ TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKUS
partner
๐Ÿ‡ฎ๐Ÿ‡น UNIVERSITA DEGLI STUDI DI TORINOIT
partner
๐Ÿ‡ช๐Ÿ‡ธ UNIVERSITAT AUTONOMA DE BARCELONAES
partner
๐Ÿ‡ช๐Ÿ‡ธ UNIVERSITAT DE BARCELONAES
partner
๐Ÿ‡ง๐Ÿ‡ช UNIVERSITE LIBRE DE BRUXELLESBE
partner
๐Ÿ‡ณ๐Ÿ‡ด UNIVERSITETET I OSLONO
partner
๐Ÿ‡จ๐Ÿ‡พ UNIVERSITY OF CYPRUSCY
partner
๐Ÿ‡ฌ๐Ÿ‡ง UNIVERSITY OF NEWCASTLE UPON TYNEGB
partner
๐Ÿ‡ฆ๐Ÿ‡ช UNIVERSITY OF SHARJAHAE
partner
๐Ÿ‡จ๐Ÿ‡ฟ USTAV MOLEKULARNI GENETIKY AV CR V.V.I.CZ
partner